Drug Type Synthetic peptide |
Synonyms |
Target |
Mechanism GP IIb/IIIa antagonists(Integrin alpha-IIb/beta-3 antagonists), thrombin inhibitors(Factor IIa inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acrocallosal Syndrome | Phase 3 | US | 02 Dec 2020 | |
Acute Coronary Syndrome | Phase 3 | US | 02 Dec 2020 | |
Non-St Elevated Myocardial Infarction | Phase 3 | US | 02 Dec 2020 | |
Stroke | Phase 2 | CN | - | |
Acute Ischemic Stroke | IND Approval | CN | 26 Jun 2023 | |
Blood Coagulation Disorders | IND Approval | CN | 07 Jun 2023 | |
Heparin-induced thrombocytopenia | Discovery | CN | 18 Sep 2021 | |
Thrombosis | Discovery | CN | 18 Sep 2021 |